The Widening Gulf in Pharmaceutical Dealmaking
Executive Summary
The pharma-to-biotech dealmaking drought, which began in 1999, continues in 2000. Drug companies have been distracted by consolidation and by their focus on later-stage products; biotechs have found funding through the capital markets. Instead, there have been plenty of biotech-to-biotech deals--little cash changes hands, but each partner's technology enables the other to reach later-stages of development, and thus keep a higher proportion of the drug's upside, granted the other has the cash to develop it.
You may also be interested in...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
Need a specific report? 1000+ reports available
Buy Reports